A Phase I/II clinical trial has demonstrated that a stem cell transplant engineered to remove the CD33 protein from donor cells using CRISPR technology can help prevent cancer recurrence in patients with acute myeloid leukemia (AML). The investigational approach, reported by Genetic Engineering & Biotechnology News, aims to protect transplanted healthy cells from being attacked by therapies that target CD33 on leukemic cells.
The trial evaluated the safety and efficacy of CRISPR-edited donor stem cells in AML patients undergoing transplant. By eliminating CD33 from donor grafts, the strategy allows post-transplant therapies—such as antibody-drug conjugates or CAR-T cells—to selectively destroy residual leukemia cells without harming the new, healthy immune cells. Early data suggest reduced relapse rates, though specific efficacy numbers were not disclosed in the source.
Regulatory milestones remain ahead; the therapy is still in early-stage clinical testing. No FDA or EMA filing has been announced, and a PDUFA date has not been set. The trial's progression will depend on demonstrating durable remission and acceptable safety profiles in a larger patient cohort.
For the developer, positive results could unlock a significant market opportunity in AML, a disease with high unmet need and frequent relapse after standard transplants. The approach also highlights CRISPR's potential beyond rare genetic disorders, moving into oncology and transplant medicine. However, competition from other CD33-targeting strategies and alternative gene-editing platforms looms.
Patient access remains distant, given the experimental nature of the therapy. Experts caution that off-target editing and immune rejection risks must be thoroughly assessed before widespread use. The results offer a promising pathway, but long-term follow-up data are essential to confirm durability and safety.